Thyroid cancer and inflammation

Molecular and Cellular Endocrinology

Volumn 321, Issue 1, 2010, Pages 94-102

  Guarino, Valentina ^a   Castellone, Maria Domenica ^a   Avilla, Elvira ^a   Melillo, Rosa Marina ^a,b  

^a Istituto di Endocrinologia ed Oncologia Sperimentale del CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Chemokine; Inflammatory cell; Thyroid cancer

Indexed keywords

B RAF KINASE; CHEMOKINE RECEPTOR CXCR4; CXCL1 CHEMOKINE; DNA; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 24; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOPROTEIN; PROTEIN PATCHED; PROTEIN RET; RAS PROTEIN; STROMAL CELL DERIVED FACTOR 1;

AUTOIMMUNE THYROIDITIS; CARCINOGENESIS; CELL DENSITY; CELL INFILTRATION; CHROMOSOME REARRANGEMENT; CYTOKINE RELEASE; DENDRITIC CELL; HASHIMOTO DISEASE; HUMAN; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MAST CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CARCINOGENESIS; THYROID PAPILLARY CARCINOMA;

ANIMALS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; HUMANS; INFLAMMATION; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS;

EID: 77950958227     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2009.10.003     Document Type: Review

References (89)

1. Alberti L., Carniti C., Miranda C., Roccato E., Pierotti M.A. RET and NTRK1 proto-oncogenes in human diseases. J. Cell Physiol. 2003, 195:168-186.
2. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
3. Baron J.A., Sandler R.S. Nonsteroidal anti-inflammatory drugs and cancer prevention. Ann. Rev. Med. 2000, 51:511-523.
4. Begum S., Rosenbaum E., Henrique R., Cohen Y., Sidransky D., Westra W.H. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol. 2004, 17:1359-1363.
5. Belletti B., Ferraro P., Arra C., Baldassarre G., Bruni P., Staibano S., De Rosa G., Salvatore G., Fusco A., Persico M.G., Viglietto G. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 1999, 18:4860-4869.
6. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., Matthews V., Schmid R.M., Kirchner T., Arkan M.C., Ernst M., Greten F.R. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
7. Borrello M.G-, Alberti L., Fischer A., Degl'innocenti D., Ferrario C., Gariboldi M., Marchesi F., Allavena P., Greco A., Collini P., Pilotti S., Cassinelli G., Bressan P., Fugazzola L., Mantovani A., Pierotti M.A. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:14825-14830.
8. Castellone M.D., Cirafici A.M., De Vita G., De Falco V., Malorni L., Tallini G., Fagin J.A., Fusco A., Melillo R.M., Santoro M. Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene 2003, 22:246-255.
9. Castellone M.D., Celetti A., Guarino V., Cirafici A.M., Basolo F., Giannini R., Medico E., Kruhoffer M., Orntoft T.F., Curcio F., Fusco A., Melillo R.M., Santoro M. Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene 2004, 23:2188-2196.
10. Castellone M.D., Guarino V., De Falco V., Carlomagno F., Basolo F., Faviana P., Kruhoffer M., Orntoft T., Russell J.P., Rothstein J.L., Fusco A., Santoro M., Melillo R.M. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 2004, 23:5958-5967.
11. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., Sidransky D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 2003, 95:625-627.
12. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
13. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
14. Daniel D., Meyer-Morse N., Bergsland E.K., Dehne K., Coussens L.M., Hanahan D. Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. 2003, 197:1017-1028.
15. De Falco V., Guarino V., Avilla E., Castellone M.D., Salerno P., Salvatore G., Faviana P., Basolo F., Santoro M., Melillo R.M. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res. 2007, 67:11821-11829.
16. De Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6:24-37.
17. Di Pasquale M., Rothstein J.L., Palazzo J.P. Pathologic features of Hashimoto's-associated papillary thyroid carcinoma. Hum. Pathol. 2001, 32:24-30.
18. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M.A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 1993, 91:1753-1760.
19. Eisenberg B.L., Hensley S.D. Thyroid cancer with coexistent Hashimoto's thyroiditis. Clinical assessment and management. Arch. Surg. 1989, 124:1045-1047.
20. Elisei R., Romei C., Vorontsova T., Cosci B., Veremeychik V., Kuchinskaya E., Basolo F., Demidchik E.P., Miccoli P., Pinchera A., Pacini F. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 2001, 86:3211-3216.
21. Evan G.I., d'Adda di Fagagna F. Cellular senescence: hot or what?. Curr. Opin. Genet. Dev. 2009, 1:25-31.
22. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993, 91:179-184.
23. Fujimoto H., Sangai T., Ishii G., Ikehara A., Nagashima T., Miyazaki M., Ochiai A. Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int. J. Cancer 2009, 125:1276-1284.
24. Fusco A., Chiappetta G., Hui P., Garcia-Rostan G., Golden L., Kinder B.K., Dillon D.A., Giuliano A., Cirafici A.M., Santoro M., Rosai J., Tallini G. Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer. Am. J. Pathol. 2002, 160:2157-2167.
25. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
26. Garcia-Rostan G., Zhao H., Camp R.L., Pollan M., Herrero A., Pardo J., Wu R., Carcangiu M.L., Costa J., Tallini G. ras Mutations Are Associated With Aggressive Tumor Phenotypes and Poor Prognosis in Thyroid Cancer. J. Clin. Oncol 2003, 21:3226-3235.
27. Gianfagna F., De Feo E., van Duijn C.M., Ricciardi G., Boccia S. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr. Genomics 2008, 9:361-374.
28. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
29. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
30. Guarino V., Faviana P., Salvatore G., Castellone M.D., Cirafici A.M., De Falco V., Celetti A., Giannini R., Basolo F., Melillo R.M., Santoro M. Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J. Clin. Endocrinol. Metab. 2005, 90:5270-5278.
31. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
32. Hansford J.R., Mulligan L.M. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J. Med. Genet. 2000, 37:817-827.
33. Houghton J., Stoicov C., Nomura S., Rogers A.B., Carlson J., Li H., Cai X., Fox J.G., Goldenring J.R., Wang T.C. Gastric cancer originating from bone marrow-derived cells. Science 2004, 306:1568-1571.
34. Iwahashi N., Murakami H., Nimura Y., Takahashi M. Activation of RET tyrosine kinase regulates interleukin-8 production by multiple signaling pathways. Biochem. Biophys. Res. Commun. 2002, 294:642-649.
35. Jo Y.S., Li S., Song J.H., Kwon K.H., Lee J.C., Rha S.Y., Lee H.J., Sul J.Y., Kweon G.R., Ro H.K., Kim J.M., Shong M. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2006, 91:3667-3670.
36. Kebebew E., Treseler P.A., Ituarte P.H., Clark O.H. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J. Surg. 2001, 25:632-637.
37. Kimura E.T., Nikiforova M.N., Zhu Z., Knauf J.A., Nikiforov Y.E., Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63:1454-1457.
38. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 2006, 6:292-306.
39. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., Fletcher J.A. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. Science 2000, 289:1357-1360.
40. Leboulleux S., Baudin E., Travagli J.P., Schlumberger M. Medullary thyroid carcinoma. Clin. Endocrinol. (Oxf.) 2004, 61:299-310.
41. Li H.C., Stoicov C., Rogers A.B., Houghton J. Stem cells and cancer: evidence for bone marrow stem cells in epithelial cancers. World J. Gastroenterol. 2006, 12:363-371.
42. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 2001, 193:727-740.
43. Lowe S.W., Sherr C.J. Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 2003, 13:77-83.
44. Maltby S., Khazaie K., McNagny K.M. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim. Biophys. Acta 2009, 1796:19-26.
45. Manie S., Santoro M., Fusco A., Billaud M. The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet. 2001, 17:580-589.
46. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 2008, 222:162-179.
47. Mechler C., Bounacer A., Suarez H., Saint Frison M., Magois C., Aillet G., Gaulier A. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements. Br. J. Cancer 2001, 85:1831-1837.
48. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., Caiazzo F., Basolo F., Giannini R., Kruhoffer M., Orntoft T., Fusco A., Santoro M. The RET/PTC-RAS-BRAF linear signalling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 2005, 115:1068-1081.
49. Nikiforova M.N., Caudill C.M., Biddinger P., Nikiforov Y.E. Prevalence of RET/PTC rearrangements in Hashimoto's thyroiditis and papillary thyroid carcinomas. Int. J. Surg. Pathol. 2002, 10:15-22.
50. Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W., Tallini G., Kroll T.G., Nikiforov Y.E. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 2003, 88:2318-2326.
51. Okayasu I. The relationship of lymphocytic thyroiditis to the development of thyroid carcinoma. Endocr. Pathol. 1997, 8:225-230.
52. Ott R.A., McCall A.R., Jarosz H., Armin A., Lawrence A.M., Paloyan E. The incidence of thyroid carcinoma in Hashimoto's thyroiditis. Am. Surg. 1987, 53:442-445.
53. Pisanu A., Piu S., Cois A., Uccheddu A. Coexisting Hashimoto's thyroiditis with differentiated thyroid cancer and benign thyroid disease: indications for thyroidectomy. Chir. Ital. 2003, 55:365-372.
54. Powell D.J., Russell J., Nibu K., Li G., Rhee E., Liao M., Goldstein M., Keane W.M., Santoro M., Fusco A., Rothstein J.L. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998, 58:5523-5528.
55. Powell D.J., Eisenlohr L.C., Rothstein J.L. A thyroid tumor-specific antigen formed by the fusion of two self proteins. J. Immunol. 2003, 170:861-869.
56. Pufnock J.S., Rothstein J.L. Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression. J. Immunol. 2009, 182:5498-5506.
57. Puxeddu E., Mitsutake N., Knauf J.A., Moretti S., Kim H.W., Seta K.A., Brockman D., Myatt L., Millhorn D.E., Fagin J.A. Microsomal prostaglandin E2 synthase-1 is induced by conditional expression of RET/PTC in thyroid PCCL3 cells through the activation of the MEK-ERK pathway. J. Biol. Chem. 2003, 278:52131-52138.
58. Puxeddu E., Knauf J.A., Sartor M.A., Mitsutake N., Smith E.P., Medvedovic M., Tomlinson C.R., Moretti S., Fagin J.A. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr. Relat. Cancer 2005, 12:319-334.
59. Rosai J., Carcangiu M.L., DeLellis R.A. Atlas of Tumor Pathology-Tumors of the Thyroid Gland. 3rd series 1992, Armed Force Institute of Pathology, Washington.
60. Rhoden K.J., Unger K., Salvatore G., Yilmaz Y., Vovk V., Chiappetta G., Qumsiyeh M.B., Rothstein J.L., Fusco A., Santoro M., Zitzelsberger H., Tallini G. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma. J. Clin. Endocrinol. Metab. 2006, 91:2414-2423.
61. Roman S., Mehta P., Sosa J.A. Medullary thyroid cancer: early detection and novel treatments. Curr. Opin. Oncol. 2009, 21:5-10.
62. Russell J.P., Shinohara S., Melillo R.M., Castellone M.D., Santoro M., Rothstein J.L. Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene 2003, 22:4569-4577.
63. Russell J.P., Engiles J.B., Rothstein J.L. Proinflammatory mediators and genetic background in oncogene mediated tumor progression. J. Immunol. 2004, 172:4059-4067.
64. Ryder M., Ghossein R.A., Ricarte-Filho J.C., Knauf J.A., Fagin J.A. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 2008, 15:1069-1074.
65. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M., Fusco A., Vecchio G., Matoskova B., Kraus M.H., et al. RET/PTC activation in human thyroid carcinomas. Science 1995, 267:381-383.
66. Santoro M., Carlomagno F., Melillo R.M., Fusco A. Dysfunction of the RET receptor in human cancer. Cell. Mol. Life Sci. 2004, 61:2954-2964.
67. Scarpino S., Stoppacciaro A., Ballerini F., Marchesi M., Prat M., Stella M.C., Sozzani S., Allavena P., Mantovani A., Ruco L.P. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 2000, 156:831-837.
68. Sheils O.M., O'eary J.J., Uhlmann V., Lättich K., Sweeney E.C. ret/PTC-1 activation in Hashimoto thyroiditis. Int. J. Surg. Pathol. 2000, 8:185-189.
69. Sclafani A.P., Valdes M., Cho H. Hashimoto's thyroiditis and carcinoma of the thyroid: optimal management. Laryngoscope 1993, 103:845-849.
70. Segal K., Ben-Bassat M., Avraham A., Har-El G., Sidi J. Hashimoto's thyroiditis and carcinoma of the thyroid gland. Int. Surg. 1985, 70:205-209.
71. Shinohara S., Rothstein J.L. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells. Oncogene 2004, 23:7571-7579.
72. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008, 267:204-215.
73. Soares P., Trovisco V., Rocha A.S., Lima J., Castro P., Preto A., Maximo V., Botelho T., Seruca R., Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580.
74. Soares P., Trovisco V., Rocha A.S., Feijão T., Rebocho A.P., Fonseca E., Vieira de Castro I., Cameselle-Teijeiro J., Cardoso-Oliveira M., Sobrinho-Simões M. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004, 444:572-576.
75. Soucek L., Lawlor E.R., Soto D., Shchors K., Swigart L.B., Evan G.I. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 2007, 13:1211-1218.
76. Stassi G., Todaro M., Zerilli M., Ricci-Vitiani L., Di Liberto D., Patti M., Florena A., Di Gaudio F., Di GesÙ G., De Maria R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003, 63:6784-6790.
77. Sumimoto H., Imabayashi F., Iwata T., Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 2006, 203:1651-1656.
78. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001, 12:361-373.
79. Todaro M., Zerilli M., Ricci-Vitiani L., Bini M., Perez Alea M., Maria Florena A., Miceli L., Condorelli G., Bonventre S., Di GesÙ G., De Maria R., Stassi G. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. Cancer Res. 2006, 66:1491-1499.
80. Tu S., Bhagat G., Cui G., Takaishi S., Kurt-Jones E.A., Rickman B., Betz K.S., Penz-Oesterreicher M., Bjorkdahl O., Fox J.G., Wang T.C. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14:408-419.
81. Ugolini C., Basolo F., Proietti A., Vitti P., Elisei R., Miccoli P., Toniolo A. Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma. Thyroid 2007, 17:389-393.
82. Xu X., Quiros R.M., Gattuso P., Ain K.B., Prinz R.A. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003, 63:4561-4567.
83. Wang J., Knauf J.A., Basu S., Puxeddu E., Kuroda H., Santoro M., Fusco A., Fagin J.A. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol. Endocrinol. 2003, 17:1425-1436.
84. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 2008, 14:6735-6741.
85. Weetman A.P. Cellular immune responses in autoimmune thyroid disease. Clin. Endocrinol. 2004, 61:405-413.
86. Williams C.S., Mann M., DuBois R.N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999, 18:7908-7916.
87. Williams D. Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat. Rev. Cancer 2002, 2:543-549.
88. Wirtschafter A., Schmidt R., Rosen D., Kundu N., Santoro M., Fusco A., Multhaupt H., Atkins J.P., Rosen M.R., Keane W.M., Rothstein J.L. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 1997, 107:95-100.
89. Zhu Z., Gandhi M., Nikiforova M.N., Fischer A.H., Nikiforov Y.E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am. J. Clin. Pathol. 2003, 120:71-77.